Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota

• Hoofdauteurs: Zhen Xiong Zhao (Auteur), Xiao Hui Tang (Auteur), Sheng Lu Jiang (Auteur), Jia Qian Pang (Auteur), Yu Bin Xu (Auteur), Dan Dan Yuan (Auteur), Ling Ling Zhang (Auteur), Hui Min Liu (Auteur), Qing Fan (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2022-12-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Hyperuricemic nephropathy (HN) is a common clinical complication of hyperuricemia. The pathogenesis of HN is directly related to urea metabolism in the gut microbiota. Febuxostat, a potent xanthine oxidase inhibitor, is the first-line drug used for the treatment of hyperuricemia. However, there have...